NanoTherapX builds nanomedicine platform for chronic skin conditions
NanoTherapX Innovations Pvt. Ltd., an IIT Bombay-incubated deep-tech startup, is developing a nanomedicine platform to treat chronic skin conditions. The company focuses on licensing its patented, plant-based therapies to pharmaceutical, biotech, and dermatology companies.
Editor, Lazyfounder

What NanoTherapX does
NanoTherapX Innovations Pvt. Ltd. is a Mumbai-based deep-tech healthcare startup incubated at IIT Bombay. The company specializes in nanomedicine solutions for dermatology and skin health, using lipid nanoparticle-based delivery systems to improve the effectiveness of therapies for chronic skin conditions.
Its flagship product, PsorisCare, is a patented, plant-based nanotherapeutic gel for psoriasis. The technology enhances skin penetration, provides sustained drug release, and reduces side effects compared to conventional steroid-based treatments. The innovation is protected by an Indian patent (No. 533382) and has been validated through preclinical studies, with results published in ACS Pharmacology & Translational Science.
Expansion beyond psoriasis
NanoTherapX is leveraging its nanotechnology platform to develop solutions for other dermatological conditions, including melasma and hair care. The company aims to bridge the gap between laboratory research and accessible healthcare solutions in India and globally.
The startup operates on a B2B licensing model, targeting pharmaceutical, biotech, dermatology, and cosmeceutical companies. It focuses on enterprises of all sizes, with a global market in mind.
Founding and recognition
NanoTherapX was incorporated in April 2025 by a multidisciplinary team comprising experts in nanomedicine, dermatology, business strategy, and finance. The founding team includes Dr. Roshan Keshari, Prof. Rohit Srivastava, and Prof. Shamik Sen.
The company has received national and international recognition, including a nomination for the Prix Galien India 2025 and inclusion in the CAS Future Leaders Top 100 list.
What this means
Lazyfounder analysis — our interpretation, not reported fact.
NanoTherapX’s focus on nanomedicine for dermatology signals a growing interest in precision therapies for chronic skin conditions. Its licensing model could appeal to pharmaceutical and biotech companies seeking clinically validated, scalable solutions. For startups and operators in the dermatology or nanotech space, NanoTherapX’s approach—combining research, patents, and preclinical validation—offers a potential blueprint for commercializing deep-tech healthcare innovations. The startup’s recognition and incubator backing may also make it a competitor or collaborator to watch in the global dermatology market.
Sources
This story is an original summary drafted with AI by Lazyfounder from the reporting listed above and checked by automated validation. Facts are attributed to their original publishers; sections marked as analysis are Lazyfounder's. Where a source is in another language, facts were machine-translated and quotations are reported, not reproduced. Read the original coverage via the links, and see our AI policy and corrections policy.
About the author
Editor, Lazyfounder
Tarun Mottlia edits LazyFounders, covering Indian startups, funding rounds, AI and product launches. Every story on the site is AI-assisted and checked against its cited sources before publication.
More stories by Tarun MottliaGet the LazyFounder Brief
Startup, funding and AI news in a five-minute read. Join the early-access list.


